Anna Brodén to be the new CEO at Reccan

We are pleased to announce that Anna Brodén, our current CTO, will take over as CEO of Reccan at the turn of the year. Anna has many years of experience from the life-science sector and a civil engineering degree from Lund University. She has played a crucial role in the development and implementation of Reccan's technical strategy. During the past 3.5 years, she has also been part of the strategic and operational management, and has the full confidence of the board to lead Reccan forward.

This change means minimal impact on the business and the company's focus remains on completing the clinical studies for our pancreatic cancer diagnostic test.

We also want to take the opportunity to thank our outgoing CEO, Malin Bornschein, who is leaving her role for new challenges outside the company. We are grateful for what Malin has achieved during her time at Reccan.